Literature DB >> 16272164

Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.

Naheed L Khan1, Shushant Jain, John M Lynch, Nicola Pavese, Patrick Abou-Sleiman, Janice L Holton, Daniel G Healy, William P Gilks, Mary G Sweeney, Milan Ganguly, Vaneesha Gibbons, Sonia Gandhi, Jenny Vaughan, Louise H Eunson, Regina Katzenschlager, Juliet Gayton, Graham Lennox, Tamas Revesz, David Nicholl, Kailash P Bhatia, Niall Quinn, David Brooks, Andrew J Lees, Mary B Davis, Paola Piccini, Andrew B Singleton, Nicholas W Wood.   

Abstract

We have established that the frequency of LRRK2 mutations in a series of 118 cases of familial Parkinson's disease is 5.1%. In the largest family with autosomal dominant, late-onset Parkinson's disease where affected subjects share a Y1699C missense mutation we provide a detailed clinical, pathological and imaging report. The phenotype in this large British kindred included asymmetrical, levodopa-responsive parkinsonism where unilateral leg tremor at onset and foot dystonia were prominent features. There was no significant abnormality of cognition but there was prominent behavioural disorder. We observed a lower age of onset in successive generations. Histopathology in one patient showed substantia nigra cell loss and Lewy body formation, with small numbers of cortical Lewy bodies. 18F-dopa positron emission tomography (PET) in another patient showed a pattern of nigrostriatal dysfunction typical of idiopathic Parkinson's disease. 18F-dopa-PET scans in unaffected family members prior to identifying the disease locus did not detect subclinical nigrostriatal dysfunction. Olfaction was assessed in affected subjects and Lewy bodies were identified in the olfactory bulb as well as cortex and brainstem of one deceased patient. In order to assess the role of mutations in this gene in other familial cases we undertook a mutation screen of all 51 exons of LRRK2 in 117 other smaller British kindreds with familial Parkinson's disease. The commonest mutation was G2019S and we also identified two novel mutations, R1941H and T2356I, in the coding sequence. These data suggest that parkinsonism caused by mutations in LRRK2 is likely to represent the commonest locus for autosomal dominant Parkinson's disease with a phenotype, pathology and in vivo imaging similar to idiopathic, late-onset Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272164     DOI: 10.1093/brain/awh667

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  108 in total

1.  Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant.

Authors:  Min Liu; Stephanie Kang; Soumya Ray; Justin Jackson; Alexandra D Zaitsev; Scott A Gerber; Gregory D Cuny; Marcie A Glicksman
Journal:  Biochemistry       Date:  2011-10-07       Impact factor: 3.162

2.  Multisystem Lewy body disease and the other parkinsonian disorders.

Authors:  J William Langston; Birgitt Schüle; Linda Rees; R Jeremy Nichols; Carrolee Barlow
Journal:  Nat Genet       Date:  2015-12       Impact factor: 38.330

3.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

4.  Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers.

Authors:  Kyle B Fraser; Mark S Moehle; Roy N Alcalay; Andrew B West
Journal:  Neurology       Date:  2016-02-10       Impact factor: 9.910

Review 5.  The pleomorphic pathology of inherited Parkinson's disease: lessons from LRRK2.

Authors:  Vincenzo Bonifati
Journal:  Curr Neurol Neurosci Rep       Date:  2006-09       Impact factor: 5.081

6.  Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease.

Authors:  Julie P Taylor; Mary M Hulihan; Jennifer M Kachergus; Heather L Melrose; Sarah J Lincoln; Kelly M Hinkle; Jeremy T Stone; Owen A Ross; Robert Hauser; Jan Aasly; Thomas Gasser; Haydeh Payami; Zbigniew K Wszolek; Matthew J Farrer
Journal:  Neurogenetics       Date:  2007-01-16       Impact factor: 2.660

7.  Olfactory dysfunction in LRRK2 G2019S mutation carriers.

Authors:  R Saunders-Pullman; K Stanley; C Wang; M San Luciano; V Shanker; A Hunt; L Severt; D Raymond; L J Ozelius; R B Lipton; S B Bressman
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

8.  Olfactory Dysfunction in Parkinson's Disease Patients with the LRRK2 G2385R Variant.

Authors:  Ming Cao; Zhu-Qin Gu; Yuan Li; Hui Zhang; Xiao-Juan Dan; Shan-Shan Cen; Da-Wei Li; Piu Chan
Journal:  Neurosci Bull       Date:  2016-10-03       Impact factor: 5.203

Review 9.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 10.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.